Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD

Estimation of Changes in Kidney Volume Growth Rate in Autosomal Dominant Polycystic Kidney Disease

(2020) Eiji Higashihara et al.   Kidney International Reports

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

(2019) Ron T. Gansevoort et al.   KIDNEY INTERNATIONAL

Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease

(2019) Kyongtae T. Bae et al.   Clinical Journal of the American Society of Nephrology

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials

(2018) Godela M. Brosnahan et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

(2018) Marie E. Edwards et al.   Clinical Journal of the American Society of Nephrology

Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease

(2018) Alan S.L. Yu et al.   KIDNEY INTERNATIONAL

Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases

(2018) Eiji Higashihara et al.   Clinical and Experimental Nephrology

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

(2017) Vicente E Torres et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

(2017) Emilie Cornec-Le Gall et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial

(2016) Olivier Devuyst et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Technical Evaluation: Identification of Pathogenic Mutations in PKD1 and PKD2 in Patients with Autosomal Dominant Polycystic Kidney Disease by Next-Generation Sequencing and Use of a Comprehensive New Classification System

(2016) Moritoshi Kinoshita et al.   PLoS One

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

(2015) Wendy E. Boertien et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial

(2015) Satoru Muto et al.   Clinical and Experimental Nephrology

Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials

(2014) M. V. Irazabal et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease

(2014) Robert W. Schrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rationale for early treatment of polycystic kidney disease

(2014) Jared J. Grantham   PEDIATRIC NEPHROLOGY

Kidney volume and function in autosomal dominant polycystic kidney disease

(2013) Eiji Higashihara et al.   Clinical and Experimental Nephrology

Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease

(2013) Olivier Devuyst et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial

(2012) Osamu Yamaguchi et al.   BJU INTERNATIONAL

Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease

(2012) A. B. Chapman et al.   Clinical Journal of the American Society of Nephrology

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation

(2012) Thien Anh Ho et al.   KIDNEY INTERNATIONAL

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

(2011) Maria V. Irazabal et al.   KIDNEY INTERNATIONAL

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES